Literature DB >> 7699461

Radiation dosimetry for bolus administration of oxygen-15-water.

C Brihaye1, J C Depresseux, D Comar.   

Abstract

UNLABELLED: We describe the development of a biokinetic model which permits an estimation of organ activities and the dosimetry of a bolus of 15O-water. The aim of this study was to estimate time-activity functions and deduce the cumulated activities in different organs so that the radiation absorbed dose values can be estimated.
METHODS: The model we used includes the right heart chambers, lungs, left heart chamber, brain, liver, kidneys, muscles, gastrointestinal tract and the remainder of the body. Activity in an organ will decay by physical decay with the decay constant, lambda, and can diffuse in the organ. An exception is the heart, where blood is ejected from the heart chambers. Depending on the location of the organ in relation to the blood sampling point, organ activities can be calculated by convolution or deconvolution.
RESULTS: The radiation absorbed dose values were estimated and an effective dose equivalent HE of 1.16 microSv/MBq (4.32 mrem/mCi) as well as an effective dose E of 1.15 microSv/MBq (4.25 mrem/mCi) were calculated. The cumulated activities in select organs measured by PET gave good agreement with the values calculated by this model.
CONCLUSION: The values of effective dose equivalent and effective dose for bolus administration of 15O-water calculated from the absorbed doses estimated by the proposed kinetic model are almost three times higher than those previously published. A total of 8700 MBq (235 mCi) of 15O-water can be administered if an effective dose of 10 mSv (1 rem) is accepted.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7699461

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  4 in total

1.  Effect of partition coefficient, permeability surface product, and radioisotope on the signal-to-noise ratio in PET functional brain mapping: a computer simulation.

Authors:  C C Martin; P A Jerabek; L D Nickerson; P T Fox
Journal:  Hum Brain Mapp       Date:  1999       Impact factor: 5.038

2.  PET radiopharmaceuticals in Europe: current use and data relevant for the formulation of summaries of product characteristics (SPCs).

Authors:  G J Meyer; S L Waters; H H Coenen; A Luxen; B Maziere; B Langström
Journal:  Eur J Nucl Med       Date:  1995-12

3.  Combined measurement of tumor perfusion and glucose metabolism for improved tumor characterization in advanced cervical carcinoma. A PET/CT pilot study using [15O]water and [18F]fluorodeoxyglucose.

Authors:  I Apostolova; F Hofheinz; R Buchert; I G Steffen; R Michel; C Rosner; V Prasad; C Köhler; T Derlin; W Brenner; S Marnitz
Journal:  Strahlenther Onkol       Date:  2014-02-18       Impact factor: 3.621

4.  Use of 55 PET radiotracers under approval of a Radioactive Drug Research Committee (RDRC).

Authors:  Isaac M Jackson; So Jeong Lee; Alexandra R Sowa; Melissa E Rodnick; Laura Bruton; Mara Clark; Sean Preshlock; Jill Rothley; Virginia E Rogers; Leslie E Botti; Bradford D Henderson; Brian G Hockley; Jovany Torres; David M Raffel; Allen F Brooks; Kirk A Frey; Michael R Kilbourn; Robert A Koeppe; Xia Shao; Peter J H Scott
Journal:  EJNMMI Radiopharm Chem       Date:  2020-11-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.